Russia's Sputnik V builders urge AstraZeneca to mix vaccines

© Reuters. FILE PHOTO: A woman holds a medical syringe and small bottle that says "Coronavirus COVID-19 Vaccine"

MOSCOW (Reuters) – Developers of the Sputnik V COVID-19 vaccine said Thursday that AstraZeneca (NASDAQ 🙂 should try to combine its experimental shot with the Russian one to increase its effectiveness.

Russia said its Sputnik V vaccine was 92% effective at protecting people from COVID-19, according to interim trial results, while AstraZeneca said its COVID-19 vaccine was 70% effective in crucial studies and could be up to 90% effective his.

"If you decide to do a new clinical trial, we recommend combining AZ uptake with human adenoviral vector uptake #SputnikV for greater effectiveness," the developers of the Russian vaccine said on their Twitter account.

"The combination of vaccines can prove important for revaccination."

AstraZeneca has announced that it will receive up to 200 million doses of its vaccine by the end of 2020.

The vaccine developed in the UK is seen as one of the best hopes for many developing countries because of its cheaper price and its ability to be shipped in normal refrigerator temperatures.

Russia has the fourth largest number of COVID-19 cases worldwide with 2,187,990 infections, behind the US, India and Brazil.

AstraZeneca will likely conduct an additional global study to evaluate the effectiveness of its vaccine, its managing director Pascal Soriot of Bloomberg News was quoted as saying after questions were raised about the results of its late-stage study.

UK Government Scientific Advisor Patrick Vallance said the main point about the AstraZeneca vaccine was that it worked when asked about those doubts.

"The main result is that the vaccine is working and that is very exciting," Vallance said during a press conference with British Prime Minister Boris Johnson.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading loss you may incur as a result of using this information.

Fusion Media or anyone involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please be fully informed about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.

Comments are closed.